Germantown, Maryland, and Hilden, Germany, December 22, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announces that, mainly as a consequence of the new U.S. tax legislation, it will take an extraordinary after-tax charge on net income of approximately $110-120 million (or about $0.47-$0.52 per share) in the fourth quarter of 2017, and... Read more
ALEX (NCT02075840/B028984) is a randomised, multicentre, open-label phase III study evaluating the efficacy and safety of Alecensa versus crizotinib in treatment-naïve people with ALK-positive NSCLC whose tumours were characterised as ALK-positive by the VENTANA ALK (D5F3) CDx Assay, a companion immunohistochemistry (IHC) test developed by Roche Tissue Diagnostics. People were randomised (1:1) to receive either... Read more
Basel, 09 December 2017 Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors Newly approved Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents as prophylaxis or on-demand Nearly 95% of children who received Hemlibra experienced zero treated bleeds Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that... Read more
Germantown, Maryland, and Hilden, Germany, December 08, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it is transferring the U.S. listing of its global shares to the New York Stock Exchange (NYSE) from the NASDAQ Global Market. The transfer to the NYSE is expected to be effective on or about... Read more
CSR Charter Read more
ANDOVER, Mass., Nov. 30, 2017 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ:MKSI), a global provider of technologies that enable advanced processes and improve productivity, today made a $50 million voluntary principal prepayment on its term loan. This prepayment is in addition to voluntary principal prepayments of $175 million made in the first three quarters of... Read more
Download PDF Read more
GE Healthcare’s priority is to provide safe products that help improve patient health. Recent publications indicate low levels of gadolinium are retained in the brain following repeated exposure to gadolinium-based contrast agents (GBCAs). We take very seriously any information concerning possible https://www.genewsroom.com/press-releases/message-our-customers Read more
Beckman Coulter Inc – Beckman Coulter, Inc. JavaScript is required for this site. Please enable JavasScript for your browser. Change Password * Indicates required fields Change Email Address * Indicates required fields Confirm Country Selection Forgot Password? * Indicates required fields Forgot your password? Please provide the email address and your last name associated... Read more